Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Jinyun Dong, Xiangdong Cheng, Weidong Zhang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8884-8915
Closed Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 46
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review
Jinyun Dong, Yuan Li, Can Hu, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108488-108488
Closed Access | Times Cited: 45
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
Nils Ott, Laura Faletti, Maximilian Heeg, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1326-1359
Open Access | Times Cited: 40
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities
Heba A. Elsebaie, Tarek F. El‐Moselhy, Eman A. El-Bastawissy, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107101-107101
Closed Access | Times Cited: 12
Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 59
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 32
μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping
Sean W. Huth, James V. Oakley, Ciaran P. Seath, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16289-16296
Closed Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment
Huang Chen, Aiwu Bian, Wenbo Zhou, et al.
ACS Central Science (2024) Vol. 10, Iss. 3, pp. 579-594
Open Access | Times Cited: 11
JAK2/STAT3 as a new potential target to manage neurodegenerative diseases: An interactive review
Siva Prasad Panda, Adarsh Kesharwani, Samaresh Datta, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176490-176490
Closed Access | Times Cited: 11
DNA Tetrahedron-Driven Multivalent Proteolysis-Targeting Chimeras: Enhancing Protein Degradation Efficiency and Tumor Targeting
Shiqing Li, Tao Zeng, Zhixing Wu, et al.
Journal of the American Chemical Society (2025)
Closed Access
Leptin, NK cells, and the weight of immunity: Insights into obesity
Arthur Gomes de Andrade, Shayenne Eduarda Ramos Vanderley, Luana Costa de Souza Marques, et al.
International Immunopharmacology (2025) Vol. 147, pp. 113992-113992
Closed Access
Discovery of Novel Fluorine-Containing Parthenolide Analogues as Potential Antitumor Agents
Xiyan Duan, Junqi Wang, Xiaoguang Huo, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117283-117283
Closed Access
Design, Synthesis and Evaluation of Diarylidenyl Piperidone-Ligated Platinum (IV) Complexes as Chemoimmunotherapeutic Agents
Zhi-Chen Mao, Lei Chen, Xiao-Man Chen, et al.
European Journal of Medicinal Chemistry (2025), pp. 117338-117338
Closed Access
Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation
Meiyu Shao, Xiaoqing Zhang, Jiamei Sun, et al.
Exploration (2025)
Open Access
Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives
Yan Li, Jian H. Song, Ping Zhou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 15, pp. 10183-10194
Closed Access | Times Cited: 33
Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance
Mehrdad Hashemi, Eisa Sabouni, Parham Rahmanian, et al.
Cellular & Molecular Biology Letters (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 17
Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4
Mao-Hua Cai, Furong Ma, Can Hu, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 90, pp. 117352-117352
Closed Access | Times Cited: 15
Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations
Huma Rafiq, Junjian Hu, Mohammed Ageeli Hakami, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
Xiaoqing Guan, Jing Yang, Weiyi Wang, et al.
Pharmacological Research (2023) Vol. 189, pp. 106703-106703
Open Access | Times Cited: 14
IL-13–induced STAT3-dependent signaling networks regulate esophageal epithelial proliferation in eosinophilic esophagitis
Sahiti Marella, Ankit Sharma, Varsha Ganesan, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1550-1568
Closed Access | Times Cited: 14
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells
Xuan Wang, Youbo Zhao, Xin Li, et al.
Nano Letters (2024)
Closed Access | Times Cited: 5
Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma
Jiazhou Ye, Xing Gao, Xi huang, et al.
Research (2024) Vol. 7
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top